Importance of New Oral Anticoagulants | DocMode
Select Page

Information


  • Price : $230


  • Language : English


  • Type : Course


  • Live On : 30 April, 2021 7:00 PM


  • Commitment : 2 weeks, 2 hour / week

About This Course

Module 1: New Anti-thrombotic Therapies for Non-Valvular Atrial Fibrillation, CAD, and Systemic Embolization

Direct oral anticoagulants (DOACs) are increasingly being used to treat patients with indications other than venous thromboembolism (VTE). This seminar will discuss newer guidelines that demonstrate DOAC use in patients with cardiac disorders. Antithrombotic therapy is a broad term encompassing anti-platelet medications and anticoagulants. The seminar will discuss data and newer practice patterns in which DOAC use in patients with coronary artery disease (CAD) is both permissible, and may offer more beneit over anti-platelet medications. The seminar will provide examples whereby the anti-platelet medication regimen must be altered in patients with a requirement for both a DOAC and anti-platelet therapy. We will inally discuss new research from the Cleveland Clinic that shows the platelet phenotype may evolve in cardiovascular disorders, and responses to antiplatelet medications may be less predictable.

Module 2: Peripheral Artery Disease – New Therapies for an Old Disease

Peripheral artery disease is an important global cardiovascular issue and is thought to affect over 120 million individuals across the world. PAD represents about 25% of the global burden of cardiovascular disease and in the US it is estimated that 8-11 millions of Americans are affected. Peripheral artery disease is thought to affect up to 54 million Indian citizens and is thought to afflict Indian diabetics at similar to higher rates as those found in European and US populations in the same age groups. This disease is commonly underdiagnosed which is unfortunate as it is the third leading cause of atherosclerotic cardiovascular disease only behind stroke and heart attack. Peripheral artery disease is a strong predictor of atherothrombotic events including major adverse cardiovascular events and major adverse limb events. Up to 20% of PAD patients will have an MI within 5 years. The risk of death and PAD patients at 5 years is anywhere between 15 and 30%. Identification of associated risk factors and early diagnosis is of the utmost importance. Less than 25% of the patients with peripheral arterial disease will have typical claudication symptoms, and a low threshold to diagnostic modalities such as ankle-brachial indices is valuable in diagnosing this entity. The importance of a thorough foot and vascular exam will be emphasized as well as consensus guidelines and generally accepted scoring systems for pulse exams and grading claudication symptoms. Other diagnostic modalities such as pulse volume recording, lower arterial duplex examinations, CT angiography, and more advanced investigations are often helpful in stratifying patients for therapy. The initial therapy for claudication is medical and includes a variety of antithrombotic choices, supervised or home exercise walking programs, and risk factor mitigation. Close vigilance and addressing the four major risk factors of atherosclerosis including smoking, diabetes, hyperlipidemia, and hypertension are important in the care of the patient with peripheral artery disease. New therapeutic options are now available from a pharmacological standpoint, including recent trials involving a direct oral anticoagulant in conjunction with an antiplatelet agent. This program will review the incidence, natural history, diagnosis, therapeutic options, and the role of atherosclerosis in peripheral artery disease.

Meet the Instructor

SCOTT J. CAMERON, M.D., Ph.D
Cleveland Clinic.

Dr. Scott Cameron is a cardiologist, vascular medicine physician, and translational research scientist with formal education in the United Kingdom (University of Edinburgh) and the United States (University of Rochester and the State Medical University of New York). He is an expert in managing acute cardiac and thrombotic emergencies, having served as faculty in the Cardiac Intensive Care Unit and as the founding member and director of a Pulmonary Embolism Response Team. His clinical experience saw him serve as the sole physician in rural, critical access hospitals with limited resources, and on the faculty of large academic medical centers including the University of Rochester in New York and Cleveland Clinic Lerner College of Medicine in Ohio. His post-graduate medical training includes clinical pathology, internal medicine, and cardiovascular disease at the Johns Hopkins Hospital in Baltimore, the New York Presbyterian Hospital (Cornell) in New York City, and the University of Rochester in Upstate New York. He also has a two degrees and a Ph.D. in pharmacology and serves as the principal investigator of a National Institute of Health-funded translational research laboratory. Scott is board-certified in internal medicine, vascular medicine, cardiovascular disease, and he is a registered physician in vascular interpretation, with COCATS II level training in comprehensive echocardiography and nuclear cardiology. He is a fellow of the American College of Cardiology and a Fellow of the Society of Vascular Medicine. Scott is a peer reviewer for 26 medical journals and serves on the Editorial Board of ATVB and he is an Associate Editor of Vascular Medicine. Scott presently serves as the Section Head of Vascular Medicine at the Cleveland Clinic in Northeast Ohio where he is as a staff physician and operates a research program focusing on thrombotic and aneurysmal disorders.

G. JAY BISHOP, M.D., FACP, FSVM, RPVI
Cleveland Clinic.

Dr. Bishop joined the Vascular Medicine Section of the Cleveland Clinic in October of 2019 after a 5-year stint as the Division Chief of Vascular Medicine at the UPMC Heart and Vascular Institute at UPMC Hamot. He did his undergraduate work at the University of New Hampshire concurrently while serving for four years as a medic in the United States Air Force. He went on to receive his medical degree from Ross University in Dominica, West Indies where he graduated with Highest Honors. He subsequently did his internship and residency and Chief Resident year in Internal Medicine at the UPMC affiliate St. Francis Medical Center in Pittsburgh PA. He is board certified in both Internal Medicine and Vascular Medicine. He currently is a Fellow of the American College of Physicians and a Fellow of the Society for Vascular Medicine. He also holds the Registered Physician in Vascular Interpretation credential from the ARDMS. Dr. Bishop maintains a national presence in his field of vascular medicine through his involvement with the Society for Vascular Medicine. He is a board member for the Society for Vascular Medicine and has been active on several SVM projects including the Low-Risk PE Toolkit, and co-edited the recently published PAD Toolkit. He also chairs a national task force on the Clinical Practice of Vascular Medicine on behalf of the SVM. He has presented and spoken nationally at specialty conferences and medical gatherings. He is a published author in peer reviewed journals with multiple articles covering various vascular topics. He has also been active in population health and disease management initiatives and serves as the Co-Medical Director for the Chautauqua New York Integrated Delivery System. Since his arrival at the Cleveland Clinic, he has been active in developing the regional vascular medicine program, spearheading clinical practice projects and serves on multiple clinical committees on behalf of the vascular medicine Section. He is the principal investigator for the ongoing COVID-19 and Thrombosis IRB projects and was recently named Associate Section Head for the division of Vascular Medicine.

What you will learn

At the completion of this course the participant will be able to:

  • understand indications for prescribing anti-thrombotic therapy, and awareness of their utilization in patients with coronary artery disease.
  • understand data using direct oral anticoagulants for the purpose of treating non-valvular atrial fibrillation, acute coronary syndrome, and systemic embolization.
  • appreciate the need to adjust anti-platelet therapy in a patient post-PCI who has an additional requirement for anticoagulation therapy.
  • understand the incidence and importance of peripheral artery disease as a frequently underdiagnosed vascular disease.
  • understand the appropriate diagnostic work up for PAD as well as optimal medical therapies and risk factor mitigation.
  • explore newer therapeutic options for peripheral artery disease including antithrombotic agents and supervised exercise therapies based on recent trials.

View Syllabus

  • Module 1: New Anti-thrombotic Therapies for Non-Valvular Atrial Fibrillation, CAD, and Systemic Embolization
  • Module 2: Peripheral Artery Disease – New Therapies for an Old Disease
Disclaimer and faculty disclosure

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by Cleveland Clinic and DocMode. In no event will Cleveland Clinic and DocMode be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

The following faculty have indicated they have no relationship which, in the context of their presentations, could be perceived as a potential conflict of interest:

Dr. Scott J. Cameron

Dr. G. Jay Bishop

This internet activity is supported by an educational grant by Glenmark Pharmaceuticals Limited.

Certificate of completion by

Cleveland Clinic

Certification Benefit

Official and Verified:

Receive an instructor-signed certificate with the institution’s logo to verify your achievement and increase your job prospects.

Easily Shareable:

Add the certificate to your CV or resume, or post it directly on LinkedIn

Boost your Profile:

Stand out from the rest by adding valuable certificates and make your profile look much more lucrative.

Proven Motivator:

Give yourself an additional incentive to complete the course

Course FAQs

Cardiologists, CPs with Cardio Practise in India

The course is organized into 2 modules and includes additional on resources specific to each one. Registration for the course is always open and participants may begin the course at any time.

USD $230

As soon as you enroll in a course, you’ll have access to all videos, quizzes, and assignments (if applicable). Peer review assignments become available once your session has officially begun.

Yes, some background knowledge pertaining the subject will be necessary. This course is directed towards MBBS/MD doctors and who have done their post-graduation in Cardiology as well as Cardiology residents.

If you pay for this course, you will have access to all of the features and content you need to earn a Course Certificate. If you complete the course successfully, your electronic Certificate will be added on a link to your Dashboard page below the completed course - from there, you can print your Certificate or add it to your LinkedIn profile.

Yes, relevant work experience is beneficial as the courses on docmode.org help practicing and aspiring healthcare professionals.